This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gajjar, D. A.
Right arrow Articles by Grasela, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gajjar, D. A.
Right arrow Articles by Grasela, D. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2003, p. 2256-2263, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2256-2263.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects

D. A. Gajjar,* A. Bello, Z. Ge, L. Christopher, and D. M. Grasela

Bristol-Myers Squibb, Princeton, New Jersey

Received 16 August 2002/ Returned for modification 11 January 2003/ Accepted 27 March 2003

Garenoxacin (T-3811ME, BMS-284756) is a novel des-F(6) quinolone that has been shown to be effective in vitro against a wide range of clinically important pathogens, including gram-positive and gram-negative aerobes and anaerobes. This study was conducted to evaluate the safety and tolerability of multiple oral doses (100 to 1,200 mg/day) of garenoxacin in healthy subjects and to determine its multiple-dose pharmacokinetics. Forty healthy male and female subjects (18 to 45 years of age) were enrolled in this randomized, double-blind, placebo-controlled, sequential, multiple- and ascending-dose study. Each subject received a once-daily oral dose of garenoxacin (100, 200, 400, 800, or 1,200 mg) or a placebo for 14 days. Blood and urine samples were collected for measurements of garenoxacin by validated liquid chromatography with dual mass spectrometry, and plasma garenoxacin concentration-time data were analyzed by noncompartmental methods. The effects of garenoxacin on Helicobacter pylori, psychometric test performance, and electrocardiograms were assessed, as was drug safety. Over the 14 days of dosing, geometric mean peak concentrations of garenoxacin in plasma (Cmax) at the 100- and 1,200-mg doses were within the ranges of 1.2 to 1.6 and 16.3 to 24 µg/ml, respectively. The corresponding values for the geometric mean area under the concentration-time curve over the dosing interval (AUC{tau}) for garenoxacin in plasma at the 100- and 1,200-mg doses were within the ranges of 11.5 to 15.7 and 180 to 307 µg · h/ml, respectively. Increases in systemic exposure to garenoxacin in terms of AUC and Cmax were approximately dose proportional over the 100- to 400-mg dose range but demonstrated increases that were somewhat greater than the dose increments at the 800- and 1,200-mg doses. Median values for the time to achieve Cmax were in the range of 1.13 to 2.50 h for all doses. The mean elimination half-life for garenoxacin in plasma appeared to be independent of dose and ranged from 13.3 to 17.8 h (day 14). Approximately 30 to 50% of an administered garenoxacin dose was excreted unchanged in the urine. At doses of 100 to 400 mg, steady-state concentrations of garenoxacin in plasma appeared to be attained by the fourth dose. Multiple oral doses of garenoxacin were well tolerated and did not demonstrate clinically significant effects on QTc or psychometric test results. Garenoxacin administered alone for 14 days at doses of ≥400 mg demonstrated activity against H. pylori. These results suggest that multiple once-daily oral doses of garenoxacin of up to 1,200 mg are safe and well tolerated and that the pharmacokinetics of garenoxacin support once-daily administration.

* Corresponding author. Mailing address: Department of Clinical Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, NJ 08543. Phone: (609) 252-4967. Fax: (609) 252-7035. E-mail: diptee.gajjar{at}bms.com.

Antimicrobial Agents and Chemotherapy, July 2003, p. 2256-2263, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2256-2263.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kiem, S., Schentag, J. J. (2008). Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid. Antimicrob. Agents Chemother. 52: 24-36 [Full Text]  
  • Krishna, G., Kisicki, J. C., Olsen, S., Grasela, D. M., Wang, Z. (2007). The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers. J Clin Pharmacol 47: 628-632 [Abstract] [Full Text]  
  • Zhanel, G. G., James, J., Derkatch, S., Laing, N., Noreddin, A. M., Hoban, D. J. (2006). Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 58: 112-116 [Abstract] [Full Text]  
  • Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M.-P., Tulkens, P. M., Van Bambeke, F. (2006). Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages. Antimicrob. Agents Chemother. 50: 841-851 [Abstract] [Full Text]  
  • Edmiston, C. E. Jr, Krepel, C. J., Kehl, K. S., Seabrook, G. R., Somberg, L. B., Almassi, G. H., Smith, T. L., Loehrl, T. A., Brown, K. R., Lewis, B. D., Towne, J. B. (2005). Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 56: 872-878 [Abstract] [Full Text]  
  • Seral, C., Barcia-Macay, M., Mingeot-Leclercq, M. P., Tulkens, P. M., Van Bambeke, F. (2005). Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 55: 511-517 [Abstract] [Full Text]  
  • Van Wart, S., Phillips, L., Ludwig, E. A., Russo, R., Gajjar, D. A., Bello, A., Ambrose, P. G., Costanzo, C., Grasela, T. H., Echols, R., Grasela, D. M. (2004). Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections. Antimicrob. Agents Chemother. 48: 4766-4777 [Abstract] [Full Text]  
  • Grohs, P., Podglajen, I., Gutmann, L. (2004). Activities of Different Fluoroquinolones against Bacillus anthracis Mutants Selected In Vitro and Harboring Topoisomerase Mutations. Antimicrob. Agents Chemother. 48: 3024-3027 [Abstract] [Full Text]  
  • Entenza, J. M., Vouillamoz, J., Glauser, M. P., Moreillon, P. (2004). Efficacy of Garenoxacin in Treatment of Experimental Endocarditis Due to Staphylococcus aureus or Viridans Group Streptococci. Antimicrob. Agents Chemother. 48: 86-92 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»